Baseline factors associated with response to ruxolitinib patients with myelofibrosis

Oncotarget

8, 79073-79086

DOI: 10.18632/oncotarget.18674

Citation Report

#	Article	IF	Citations
1	Developmental Therapeutics in Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S43-S52.	0.2	14
2	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematological Oncology, 2018, 36, 561-569.	0.8	46
3	The role of JAK2 inhibitors in MPNs 7 years after approval. Blood, 2018, 131, 2426-2435.	0.6	40
4	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leukemia Research, 2018, 74, 86-88.	0.4	23
5	Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis. International Journal of Molecular Sciences, 2018, 19, 898.	1.8	35
6	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. British Journal of Haematology, 2018, 183, 35-46.	1.2	7
7	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâŽ. Seminars in Hematology, 2018, 55, 248-255.	1.8	24
8	Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. Current Hematologic Malignancy Reports, 2019, 14, 460-468.	1.2	14
9	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. Annals of Hematology, 2019, 98, 1933-1936.	0.8	5
10	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 2019, 37, 418-423.	0.8	3
11	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	0.8	10
12	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	2.0	106
13	JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. HemaSphere, 2020, 4, e424.	1.2	49
14	Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers, 2020, 12, 2278.	1.7	15
15	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 2020, 4, 3677-3687.	2.5	51
16	Management of myelofibrosis after ruxolitinib failure. Annals of Hematology, 2020, 99, 1177-1191.	0.8	62
17	Primary analysis of JUMP, a phase 3b, expandedâ€access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. British Journal of Haematology, 2020, 189, 888-903.	1.2	61
18	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. Hematological Oncology, 2020, 38, 372-380.	0.8	15

#	Article	IF	Citations
19	Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to. Annals of Hematology, 2020, 99, 1161-1176.	0.8	9
20	Low-dose ruxolitinib shows effective in treating myelofibrosis. Annals of Hematology, 2021, 100, 135-141.	0.8	4
21	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). American Journal of Hematology, 2021, 96, 69-79.	2.0	40
22	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2021, 193, 356-368.	1.2	19
23	Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leukemia and Lymphoma, 2021, 62, 918-926.	0.6	19
24	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer Journal, 2021, 11, 4.	2.8	41
25	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer, 2021, 127, 2657-2665.	2.0	14
26	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia, 2021, 35, 3455-3465.	3.3	25
27	SOHO State of the Art Updates and Next Questions: Identifying and Treating â€œProgressionâ€•in Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 641-649.	0.2	11
28	Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey. Turkish Journal of Medical Sciences, 2021, 51, 1033-1042.	0.4	0
29	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System lowâ€, intermediateâ€1â€, intermediateâ€2â€, and highâ€risk myelofibrosis in JUMP, a Phase 3b, expandedâ€access study. Hematological Oncology, 2021, 39, 558-566.	0.8	11
30	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). Leukemia and Lymphoma, 2022, 63, 189-198.	0.6	3
31	Standard care and investigational drugs in the treatment of myelofibrosis. Drugs in Context, 2019, 8, 1-16.	1.0	4
32	Early Response and Long-Term Outcomes of Ruxolitinib Therapy in Myelofibrosis: Multicenter Retrospective Study in 10 Centers of the Russian Federation. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 335-345.	0.1	3
33	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUXâ€IOL study. British Journal of Haematology, 2022, 197, 190-200.	1.2	7
34	Iron chelation for myelofibrosisâ€related anaemia during treatment with a Janus kinase inhibitor. British Journal of Haematology, 2022, , .	1.2	0
35	A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Advances, 2022, 6, 1855-1864.	2.5	47
36	How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. Cells, 2022, 11, 553.	1.8	5

#	Article	IF	Citations
37	Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology, 2022, 27, 23-31.	0.7	6
38	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronicâ€phase myelofibrosis. Cancer, 2022, 128, 2449-2454.	2.0	7
39	The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. Cancer, 2022, , .	2.0	8
40	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology, 2022, 29, 4970-4980.	0.9	2
41	Recent progress of JAK inhibitors for hematological disorders. Immunological Medicine, 2023, 46, 131-142.	1.4	6
42	Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, e19-e26.	0.2	1
43	Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a realâ€life setting: An Italian MYNERVA Project. Cancer Medicine, 2023, 12, 8166-8171.	1.3	3
44	How I manage anemia related to myelofibrosis and its treatment regimens. Annals of Hematology, 2023, 102, 689-698.	0.8	1
45	Palpable spleen size is differently prognostic in primary and secondary myelofibrosis. Leukemia and Lymphoma, 2023, 64, 893-896.	0.6	0
46	Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORTâ€I and COMFORTâ€II studies. Cancer, 2023, 129, 1681-1690.	2.0	6
47	MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-NaÃ¯ve Myelofibrosis. Journal of Clinical Oncology, 2023, 41, 4993-5004.	0.8	19
48	Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer, 2023, 129, 1704-1713.	2.0	5
49	Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leukemia and Lymphoma, 2023, 64, 1063-1081.	0.6	7
52	Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib. Blood Cancer Journal, 2023, 13, .	2.8	0
59	JAK Inhibitors for the Management of Myeloproliferative Neoplasms. , 2023, , 567-576.		0